Prostate cancer (PCa) is one of the most common cancers in European males. Although
therapeutic approaches have changed in recent years, and several new drugs have been …

With advances in the discovery of the clinical and molecular landscapes of prostate cancer
(PCa), implementation of precision medicine-guided therapeutic testing in the clinic has …

Tumor cells adapt to diverse survival strategies defying our pursuit of multimodal cancer
therapy. Prostate cancer (PCa) is an example that is resistant to one of the most potent …

Cancer cells proliferate, differentiate and migrate by repurposing physiological signalling
mechanisms. In particular, altered calcium signalling is emerging as one of the most …

Over the past 5 years, the advent of combination therapeutic strategies has substantially
reshaped the clinical management of patients with advanced prostate cancer. However …

Reactive stroma is a tissue feature commonly observed in the tumor microenvironment of
prostate cancer and has previously been associated with more aggressive tumors. The aim …

Chronic inflammation is associated with both benign conditions and cancer. Likewise,
inflammatory cells are quite common in benign prostatic hyperplasia (BPH) and prostatic …

Androgen receptor (AR) targeting remains the gold standard treatment for advanced
prostate cancer (PCa); however, treatment resistance remains a major clinical problem. To …

Gastric cancer (GC) is the third cause of cancer-related mortality worldwide and is often
diagnosed at advanced stages of the disease. This makes the development of more …

Androgen Receptor (AR) activity in prostate stroma is required to maintain prostate
homeostasis. This is mediated through androgen-dependent induction and secretion of …